Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.12
+261.3%
$0.06
$0.00
$0.78
$5.13M1.185,773 shs195 shs
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
$4.64
$2.76
$7.40
$8.98M1.7810,937 shs351,000 shs
NextTrip, Inc. stock logo
NTRP
NextTrip
$3.79
+3.8%
$0.96
$0.68
$3.85
$29.01M1.5448,850 shs19,608 shs
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
$1.34
+5.2%
$1.46
$0.85
$4.42
$58.05M1.21474,980 shs141,463 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
+261.26%+64.12%+261.26%+301.00%-41.55%
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
NextTrip, Inc. stock logo
NTRP
NextTrip
+3.99%+8.31%+78.05%-38.03%+93.12%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
+4.10%-15.89%-9.93%+20.95%-56.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
NextTrip, Inc. stock logo
NTRP
NextTrip
1.6948 of 5 stars
3.03.00.00.00.60.01.3
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2.4046 of 5 stars
3.74.00.00.02.30.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00
N/AN/AN/A
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
0.00
N/AN/AN/A
NextTrip, Inc. stock logo
NTRP
NextTrip
2.00
Hold$5.0031.93% Upside
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
3.33
Buy$9.00573.65% Upside

Current Analyst Ratings Breakdown

Latest ADXS, NTRP, DFFN, and PDSB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
6/11/2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$3.24M1.58N/AN/A($2.06) per share-0.06
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
N/AN/AN/AN/A$6.97 per shareN/A
NextTrip, Inc. stock logo
NTRP
NextTrip
$500K57.99N/AN/A$4.16 per share0.91
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/A$0.51 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$7.98N/AN/AN/AN/AN/AN/A
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
-$15.59MN/A0.00N/AN/AN/A-69.96%-62.98%N/A
NextTrip, Inc. stock logo
NTRP
NextTrip
-$10.12MN/A0.0031.58N/A-2,015.64%-580.52%-165.33%N/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$37.61M-$0.94N/AN/AN/AN/A-150.59%-69.15%8/12/2025 (Estimated)

Latest ADXS, NTRP, DFFN, and PDSB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
-$0.25-$0.21+$0.04-$0.21N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
N/AN/AN/AN/AN/A
NextTrip, Inc. stock logo
NTRP
NextTrip
N/AN/AN/AN/AN/A
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/A
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
N/A
10.71
10.71
NextTrip, Inc. stock logo
NTRP
NextTrip
N/A
0.96
0.96
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
0.29
2.33
2.33

Institutional Ownership

CompanyInstitutional Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
7.18%
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
9.95%
NextTrip, Inc. stock logo
NTRP
NextTrip
3.81%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
26.84%

Insider Ownership

CompanyInsider Ownership
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.63%
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
1.80%
NextTrip, Inc. stock logo
NTRP
NextTrip
9.60%
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
9.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2042.63 million42.36 millionNot Optionable
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
132.04 million2.00 millionNot Optionable
NextTrip, Inc. stock logo
NTRP
NextTrip
57.65 million6.92 millionNo Data
PDS Biotechnology Corporation stock logo
PDSB
PDS Biotechnology
2045.71 million41.51 millionOptionable

Recent News About These Companies

PDS Health adds practices in 5 states
PDS arm inks pact to acquire 60% stake in GSC Link
PDS Biotechnology's (PDSB) Buy Rating Reiterated at HC Wainwright
PDS Biotechnology Corporation (PDSB) - Yahoo Finance
PDS Health ranked among most community-minded companies
Unpacking the PDS Phenomenon

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ayala Pharmaceuticals stock logo

Ayala Pharmaceuticals NASDAQ:ADXS

$0.12 +0.09 (+261.26%)
As of 07/2/2025 11:38 AM Eastern

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Diffusion Pharmaceuticals stock logo

Diffusion Pharmaceuticals NASDAQ:DFFN

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.

NextTrip stock logo

NextTrip NASDAQ:NTRP

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.

PDS Biotechnology stock logo

PDS Biotechnology NASDAQ:PDSB

$1.34 +0.07 (+5.20%)
Closing price 03:46 PM Eastern
Extended Trading
$1.34 0.00 (-0.07%)
As of 04:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.